Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Liposarcoma × Sugars × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leiomyoma 2 Warts 1 Papilloma 1 Liposarcoma 1 HIV Infections 1 Anemia 1 Acquired Immunodeficiency Syndrome 1

Interventions

Trabectedin 4 Doxorubicin 3 brigimadlin 2 belinostat 2 Fulvestrant 2 Dexamethasone 2 toripalimab 1 tanespimycin 1 soblidotin 1 siremadlin 1 selinexor 1 ridaforolimus 1 ribociclib 1 pembrolizumab 1 olaratumab 1 milademetan 1 enzalutamide 1 cemiplimab 1 atezolizumab 1 TTI-621 1 Sugars 1 Midazolam 1 Letrozole 1 Imatinib Mesylate 1 Histamine H2 Antagonists 1 Fluorouracil 1 Famotidine 1 Docetaxel 1 Dacarbazine 1 Clinical Trials, Phase II as Topic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡